ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements with these filters
Par Drugs & Chemicals Ltd reported revenue from operations of ₹27.4 Cr (-4.5% YoY) and net profit of ₹2.6 Cr (-36.6% YoY) for Q2 FY27.
Par Drugs and Chemicals Limited will hold a board meeting on October 29, 2026, to consider and approve its half-yearly unaudited financial results.
The company submitted the routine Regulation 74(5) compliance certificate from its RTA regarding share dematerialization for the quarter ended September 30, 2026.
Par Drugs re-appointed its statutory auditor and executive director/CEO. These appointments were approved at the company's 27th Annual General Meeting.
Par Drugs and Chemicals Limited held its 27th Annual General Meeting on September 26, 2026. Management reviewed the company's financial performance and business affairs during the session.
Par Drugs and Chemicals Limited is notifying shareholders about access to the FY 2025-26 Annual Report and 27th AGM notice via web-link.
Par Drugs and Chemicals Limited has re-appointed M/s. Siddhpura & Co. as Internal Auditor and M/s. Maulin Shah & Associates as Cost Auditor.
Par Drugs and Chemicals Limited has scheduled its 27th Annual General Meeting for September 26, 2026, in Vadodara to transact scheduled ordinary and special business.
Par Drugs & Chemicals Ltd reported revenue from operations of ₹103.7 Cr (+2.7% YoY) and net profit of ₹13.1 Cr (-2.2% YoY) for Q4 FY26.
Par Drugs and Chemicals Limited has scheduled a board meeting for August 22, 2026. The meeting will address other business matters.
Par Drugs & Chemicals Ltd reported revenue from operations of ₹31.3 Cr (+20.4% YoY) and net profit of ₹4.7 Cr (+42.4% YoY) for Q1 FY27.
Par Drugs & Chemicals Ltd submitted a SEBI Regulation 74(5) compliance certificate for the quarter ended June 30, 2026. The filing confirms dematerialisation of securities with MUFG Intime India.
Par Drugs and Chemicals secured a rectification order deleting a tax demand of ₹0.20 Crore. The demand is now nil, with no material financial impact.
Par Drugs and Chemicals received a rectification order deleting a prior income tax demand. The demand is now nil, with no financial impact.
Par Drugs received a ₹0.20 Crore income tax demand due to clerical errors. Management expects the demand to be recomputed to nil following rectification.
Par Drugs & Chemicals Ltd reported revenue from operations of ₹19.6 Cr (-12.1% YoY) and net profit of ₹0.9 Cr (-47.1% YoY) for Q4 FY26.
Par Drugs and Chemicals Limited approved its FY2026 audited financial results and authorized a ₹90 Crore investment limit. The board also renewed its ₹1.61 Crore banking facility.
Par Drugs approved its FY2026 audited results and renewed a ₹1.61 Crore banking facility. The board also noted a ₹25.14 Lakh employee bonus payment.
Par Drugs and Chemicals Limited submitted its quarterly compliance certificate under SEBI Regulations for the period ended March 31, 2026. The registrar, MUFG Intime India, confirmed that share certificates received for dematerialisation were processed and cancelled within prescribed timelines. This is a routine administrative filing with no material financial impact.